BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) filed an S-1 registration statement with the Securities and Exchange Commission on August 29, 2025, initiating the regulatory process to complete a blank-check company initial public offering focused on the oncology and biopharmaceutical sector. The company carries the BridgeBio brand, which is associated with cancer and genetic disease drug development. As of the filing date, BBOT remained in the registration phase and had not yet completed its IPO, placing it among a cohort of 2025-vintage healthcare-focused special purpose acquisition companies targeting partners in cancer therapeutics. Sign up on SpacDesk for full filing data, sponsor profiles, and deal timelines on BBOT and hundreds of other active SPACs.